Hikma Adds Columbus Generic Drug Capacity
Healthcare procurement teams should note added domestic generic production, with full Columbus operation projected for next year.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you think big drug manufacturers expanding local plants helps lower your family's medicine costs?
Hikma Pharmaceuticals, a Jordanian-founded drugmaker, invested $267 million to expand its facilities in Columbus and Bedford, adding production capacity for generic medicines made in Ohio.
Why it matters
The expansion adds manufacturing capacity for generic medicines in Columbus, a city that now hosts a visible new production build-out in pharmaceuticals. For operators in healthcare supply chains, it signals continued investment in domestic generic drug manufacturing.
Hikma is investing $267 million across its Columbus and Bedford facilities, with 350 new jobs projected from the expansion. The new Columbus wing broke ground sixteen months before the recent visit, and the extraction offers no prior-year or industry benchmark for these figures.
The players
Hikma Pharmaceuticals
Jordanian-founded generic drugmaker with US manufacturing operations in Ohio and Bedford, expanding domestic production capacity.
Mike Carey
US Congressman who visited Hikma's Columbus manufacturing facility and toured its expanded production lines.
The details
The expansion runs through a new wing at Hikma's Columbus facility, whose groundbreaking came sixteen months before a recent site visit. The new wing is projected to be fully operational next year, which would bring added generic medicine output into Hikma's Ohio production base. Congressman Mike Carey toured the expanded production lines and met with employees during that visit.
Timeline
Sixteen months before the recent visit: groundbreaking of Hikma's new Columbus wing.
Recent visit (prior to November 3, 2026): Congressman Mike Carey toured the Columbus facility.
2027: the expanded Columbus wing is projected to be fully operational.
Market Landscape
Hikma's $267 million investment places it among drugmakers adding US generic production capacity at existing sites rather than building entirely new plants. The extraction does not name a specific prior deal or industry cycle to compare against, so the broader competitive context is limited to Hikma's own multi-site expansion.
Operators in healthcare supply chains should track whether domestic generic capacity expansions like this one affect sourcing options and lead times for generic medicines. Procurement teams may want to monitor the Columbus wing's projected start of full operation in 2027 when evaluating future supplier relationships.
The takeaway
Domestic generic production expansions can change supplier availability and sourcing terms over time. Procurement leads should watch for confirmed start dates for the Columbus wing before adjusting near-term supply plans.
Further reading
For broader context on drug production trends, see the Healthcare section.
Source note: This article includes information reported by وكاله عمون الاخباريه.
Live Poll
Do you think big drug manufacturers expanding local plants helps lower your family's medicine costs?
